Literature DB >> 1760886

Long term follow-up after surgical removal of pheochromocytoma--observations in 61 patients.

P Pruszczyk1, W Januszewicz, T Feltynowski, J Chodakowska, B Wocial, R Pachocki, J Nielubowicz, M Szostek.   

Abstract

89 patients were operated on for pheochromocytoma. 61 patients (37 women and 24 men) were available for extended follow-up. The final survey, performed 79.1 +/- 66.9 months postoperatively, provided data on survival, blood pressure tumor recurrence, malignant metastatic lesions, cardiovascular complications and coexisting diseases. There were 4 deaths during the follow-up period, including 2 instances of malignant pheochromocytoma. Permanent normalization of blood pressure was achieved in 38 patients (62.3%). This hypotensive effect was noted in 79.2% of patients with preoperative paroxysmal hypertension and in 40.8% of those with sustained hypertension. Permanent or re-developing postoperative hypertension was noted in 23 (37.7%) patients. This includes 4 cases of malignant pheochromocytoma, 4 cases of recurrent benign pheochromocytoma and 15 cases of essential hypertension. Cardiovascular complications during follow-up were rare and concerned the patients with essential hypertension diagnosed postoperatively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760886     DOI: 10.3109/10641969109042121

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  2 in total

1.  Re-operative Surgery for Pheochromocytoma-Paraganglioma: Analysis of 13 Cases from a Single Institution.

Authors:  Dhiraj John Sonbare; Deepak Thomas Abraham; Simon Rajaratnam; Nihal Thomas; Marie Therese Manipadam; Rekha Pai; Paul Mazhuvanchary Jacob
Journal:  Indian J Surg       Date:  2017-06-05       Impact factor: 0.656

2.  Clinical experiences of pheochromocytoma in Korea.

Authors:  Kwang Hyun Kim; Jae Seung Chung; Won Tae Kim; Cheol Kyu Oh; Yun Byung Chae; Ho Song Yu; Won Sik Ham; Young Deuk Choi
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.